There is now little doubt that glycaemic control and duration of diabetes are major determinants of DPN. In addition, a major European prospective study has demonstrated that potentially modifiable, traditional markers of macrovascular disease such as hyperlipidaemia, hypertension, obesity and tobacco smoking are also independent risk factors for DPN. 3 
burning pain' appeared to be a better discriminator of the presence of painful neuropathy than 'pricking sensation', which was less specific. 6 Further categorisation as to the type and frequency of different pain qualities (spontaneous sensations manifesting as symptoms or elicited in examination as clinical signs e.g. hyperalgesia and allodynia) is necessary.
In general, the patient should be allowed to describe his or her symptoms without too many leading questions. Ordinary walking may be described by some patients as an unusual sensation of walking barefoot on 'pebbles' or 'scalding sand', for example. Others relate odd sensations of their feet being swollen. There is a large spectrum of severity of the many symptoms of DPNP. Some may have mild symptoms in a toe or two; others may have continuous painful symptoms involving both legs and extending to the upper limbs. When the latter is the case, sleep pattern is usually disturbed. Perhaps unsurprisingly, therefore, such patients may be so disabled by the pain as to experience a reduction in their daily activities and may even lose their employment, are profoundly depressed and experience a poor quality of life (QoL). 4 Therefore, the impact of the pain on daily living, work life, recreational activity and QoL must be assessed.
There are very few studies looking at the prevalence of DPNP specifically and these report a prevalence rate of 7-26% reflecting differing criteria used to define neuropathic pain. 7 In the EURODIAB prospective study nearly a quarter developed neuropathic symptoms over a seven-year period. 3 Thus, a significant number of our diabetic patients suffer from neuropathic pain.
Neuropathic pain may present acutely within the context of very poor glycaemic control, typically in type 1 subjects (acute painful neuropathy of poor glycaemic control), or after initiation of treatment (acute painful neuropathy of rapid glycaemic control). 8 These acute syndromes are relatively rare compared with the chronic painful neuropathy associated with DPN. There is a rapid build-up of unpleasant sensory symptoms within weeks leading to persistent lower-limb burning pain, paraesthesiae and allodynia, with nocturnal exacerbation and depression. 8 There may also be marked precipitous weight loss. Sensory loss is often mild or absent, and there are no motor signs. Thankfully, in acute painful neuropathies there is complete resolution of symptoms within a year. 8 These patients may well need to be investigated with lumbar-sacral magnetic resonance imaging (MRI). The quality and severity should be assessed, preferably using a suitable scale, so that response to treatment may be evaluated. 4, 7 An empathic approach with a multidisciplinary support is essential. 4 There is now little doubt that good blood-sugar control can prevent/delay the onset of DPN. 9 However, there are no controlled studies that show the efficacy of this intervention in reducing the severity of DPNP. Nevertheless, despite the lack of evidence there is a general consensus that intensive blood glucose control should be the first step in the treatment of any form of diabetic polyneuropathy. Traditional markers of large-vessel disease including hypertension, obesity, hyperlipidaemia and smoking also appear to be independent risk factors for DPN and therefore need to be effectively managed. 3 Pharmacological treatment of DPNP is not entirely satisfactory as currently available drugs can be ineffective in some patients and may also be complicated by side effects. 7 Tricyclic antidepressants (TCAs) such as amitriptyline (25-150mg/day in divided doses) have been used as first-line agents for many years, but many patients fail to respond to them and side effects are frequent. 7 Serotonin noradrenalin reuptake inhibitors (SNRIs) such as duloxetine effectively block the 5-hydroxytryptamine (5-HT) and noradrenaline transporters, leading to inhibition of excitatory impulse generation and reduced pain perception. 7 The efficacy of duloxetine in DPNP has been investigated in three trials and the 60mg/day and 120mg/day doses appear to be efficacious and well tolerated. The α2δ agonist anticonvulsants gabapentin and, more recently, pregabalin are also effective first-line agents for DPNP. There have been at least three clinical trials that show the efficacy of pregabalin at a dose of 150mg twice/day and 300mg twice/day in DPNP. 7 Second-line agents include opiates such as tramadol (50-100mg four times/day) and oxycodone 20-40mg/day. Side effects include typical opiate-type adverse events such as constipation and sedation. Refractory cases may be treated with membrane stabilisers including mexiletine and intravenous lignocaine; the antioxidant, α-lipoic acid and the substance-P depleter, topical capsaicin. 7 Depending on contraindications and co-morbidities
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